Precision BioSciences, Inc.

As of June 30, 2026, Precision BioSciences, Inc. carries a market capitalization of 182.92M, placing it among publicly traded companies globally. Its enterprise value stands at 130.89M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Precision BioSciences, Inc.'s next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, Precision BioSciences, Inc. has 26.43M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.57, and the price-to-book ratio stands at 4.61.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.32 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 130.89M versus a market cap of 182.92M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Precision BioSciences, Inc. maintains a current ratio of 12.82, meaning it holds 12.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 62.04, indicating elevated leverage, while an interest coverage ratio of -25.59 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Precision BioSciences, Inc. posted a negative return on equity (ROE) of -132.91, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -44.91, reflecting losses generated across the asset base. The company generates approximately 505,597.97 in revenue per employee across its workforce of 78.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Precision BioSciences, Inc.'s stock has gained approximately 1.18% over the past 52 weeks. The 50-day moving average sits at 6.13, while the 200-day moving average is 5.62.

Over the twelve months ended June 30, 2026, Precision BioSciences, Inc. generated 39.44M in revenue and converted that into -46.16M in net income, yielding earnings per share of -2.30. EBITDA reached -29.59M, while operating income came in at -31.86M.

As of June 30, 2026, Precision BioSciences, Inc. holds 76.63M in cash and equivalents against 24.60M in total debt, resulting in a net debt position of -55.72M. Total book value stands at 39.64M, with working capital of 73.88M providing operational flexibility.

Precision BioSciences, Inc. produced -45.43M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -426,271.10 in capital expenditures, free cash flow totaled -45.85M - equivalent to -2.25 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -80.78 and net profit margin of -117.04 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -32.53: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -38.24, meaning Precision BioSciences, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Precision BioSciences, Inc.'s most recent stock split took place on February 14, 2024 with a 30:1 split ratio.

As of June 30, 2026, Precision BioSciences, Inc. has an Altman Z-Score of -4.73, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.